Immatics

Tubingen, Germany Founded: 2000 • Age: 26 yrs Listed
T-cell-based immunotherapies for cancer treatment are developed.

About Immatics

Immatics is a publicly listed company based in Tubingen (Germany) founded in 2000. T-cell-based immunotherapies for cancer treatment are developed. Immatics has raised $236.4 million across 9 funding rounds from investors including 3i Group, European Union and KfW. The company has 423 employees. Its website immatics.com draws about 17 thousand monthly visits. Immatics offers products and services including Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT. Its focus areas include Life Sciences, Cell Therapy, Adoptive Cell Therapy and T-Cell. Its legal entity is Immatics N.V.

Company details

Founded in 2000 and based in Tubingen, Germany, the company operates in the biotechnology sector, focusing on cancer immunotherapies. A proprietary platform called XPRESIDENT is utilized to identify and validate cancer-specific antigens. Adoptive cell therapies and bispecific T-cell receptors are subsequently developed for cancer treatment. The IMA101 product is generated through the ACTolog approach, employing T-cells from peripheral blood with targeted selectivity.

  • Headquarters Tubingen, Germany
  • Employees 423
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website immatics.com
  • Social LinkedIn X Instagram
  • Legal Name Immatics N.V.
Key Metrics
  • Annual Revenue
    $54.47 M (USD)
    -67.68
    as on Dec 31, 2025
  • Net Profit
    -$221.71 M (USD)
    -1446.84
    as on Dec 31, 2025
  • EBITDA
    -$196.77 M (USD)
    -587.27
    as on Dec 31, 2025
  • Total Equity Funding
    $236.4M (USD)

    in 9 rounds

  • Latest Funding Round
    $35M (USD), Post-IPO

    Jul 2023

  • Investors
    3i Group

    & 15 more

  • Employee Count
    423

Products & Services of Immatics

Immatics offers a comprehensive portfolio of products and services, including Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT.

Adoptive Cell Therapies
Cancer Immunotherapy

T cell-based treatments targeting solid tumors in clinical trials.

TCR Bispecifics
Biotech Product

Bispecific antibodies for enhancing T cell responses against cancer.

Next-generation ACT
Advanced Therapies

Innovative cell therapies for improved cancer treatment efficacy.

Funding Insights of Immatics

Immatics has successfully raised a total of $236.4M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $236.4M
  • Total Rounds 9
  • Last Round Post-IPO β€” $35M
  • First Round $10.09M

    (Mar 2004)

  • Investors Count 16

All 9 funding rounds of Immatics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2023$35MPost-IPO––
Aug 2020Post-IPO––
Oct 2017$58MSeries E–Dievini, Amgen Business Development
Jan 2016$1.41MGrant––
Oct 2013$46MSeries D–Wellington Partners Venture Capital, Dievini
–
Jun 2013Series C–b2venture
–
Sep 2010$70.35MSeries C–MIG Fonds
Feb 2007$51.96MSeries B–3i Group, Wellington Partners Venture Capital
Mar 2004$10.09MSeries A–Wellington Partners Venture Capital, 3i Group
Valuation history

16 investors in total: 16 institutional.

Investors in Immatics

Immatics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include 3i Group, European Union and KfW.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital and private equity investments are managed.
asiaalpha.comNew York, United States
Investments are made in early-stage healthcare startups.
wellington-partners.comMunich, Germany
Investments are made in life and health sciences companies.
dievini.deGermany
Venture capital investments are facilitated by Amgen-backed entity.
amgenbd.comThousand Oaks, United States
Venture capital is provided to innovative startups by b2venture.
b2venture.vcSt. Gallen, Switzerland
Venture capital investments in technology companies are managed by MIG Fonds.
mig-fonds.deGermany
Private equity firm focused on mid-market businesses
19453i.comLondon, United Kingdom
NTEC Kuwait is engaged in technology and knowledge transfer services.
ntec.com.kwKuwait City, Kuwait
Merifin Capital is recognized as a European private investment group.
merifin.comBrussels, Belgium
Premium access

Investor details for Immatics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Immatics

134 people are tracked at Immatics (56 in leadership, 13 in board & advisors, 65 in team); the tracked headcount is 423.

NameRoleGroup
Carsten Reinhardt
Managing Director & CDOLeadership
Ephraim Hofsäß
Vice President SEC Reporting & AccountingLeadership
Amie Krause
Chief People OfficerLeadership
Cindy Greysen
Executive Director, Medical AffairsLeadership
Silvia Kestler
Associate Director Clinical OperationsLeadership
Venkat Ramanan
Chief Financial OfficerLeadership
Tanja Kieschoweit
Director Clinical Operations | Team Lead Site OperationsLeadership
Michael Mølhøj
VP, CMCLeadership
Rainer Kramer
Managing Director & Chief Business OfficerLeadership
Cedrik Britten
Chief Medical OfficerLeadership
Toni Weinschenk
Chief Innovation OfficerLeadership
Harpreet Singh
CEOLeadership
Dominik Maurer
VP, Immunology & Site Head TuebingenLeadership
Andrea Mayer
Vice President, Global Head of Clinical SciencesLeadership
Nina Stahl
Associate Director, Global Patient SupplyLeadership
Khalel Iman
Associate Director, Clinical DevelopmentLeadership
Bettina Brackertz
Associate Director Clinical SafetyLeadership
Claudia Blattner
Vice President Business DevelopmentLeadership
Ali Mohamed
VP, CMCLeadership
Paula Franson
VP, Medical AffairsLeadership

114 more people are available in the full profile.

Premium access

Complete people profiles for Immatics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Immatics

Immatics is a publicly listed company on the NASDAQ with ticker symbol IMTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date02 Jul 2020
  • Listed onNASDAQ: IMTX
  • Listed entityImmatics N.V.
  • Exchange sectorHealth technology
  • ISINNL0015285941
  • Share price$6.83 (-5.27% on the day) · 2026-10-13
  • Market capitalisation$1.02B
  • EPS (diluted, trailing year)$-1.85
  • Volume (last session)928,583

Financials of Immatics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$54.5M-$221.7M-$196.8M
2024$168.6M$16.5M-$28.6M
2023$58.4M-$102.3M-$103.4M
2022$181.6M$39.4M$38.8M
2021$41.1M-$110.3M-$96.2M
Premium access

Detailed financial statements for Immatics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Immatics

4 dated milestones of Immatics across 23 years, from founding to its latest funding, stage changes and deals.

  1. Founded Immatics is founded.
  2. Funding First funding round of $10.1M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $35.0M.

Web traffic of Immatics

The website of Immatics (immatics.com) receives about 17.1K visits a month and ranks #1,492,078 among all websites worldwide, #1,962 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    17.1K

    ▼ 8.1% vs previous month

  • Unique visitors
    7.3K

    per month

  • Global rank
    #1,492,078

    among all websites

  • Category rank
    #1,962

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Immatics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
bioregio-stern.de
100%
6.8K#2,397,204View details
transkript.de
transkript.de
98%
#2,698,949–
ovesco.com
74%
6K#3,167,330View details
fiercebiotech.com
66%
858.3K#81,022View details
cegat.com
62%
30.6K#1,030,162View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Immatics

Premium access

Complete news archive for Immatics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Immatics

Immatics was founded in 2000 and raised its 1st funding round 4 years after it was founded.

Immatics is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.

Immatics is a funded company, having raised a total of $236.4M across 9 funding rounds to date. The company's 1st funding round was a Series A of $10.09M, raised on Mar 2004.

Immatics has 423 employees.

Annual revenue of Immatics is $54.47M as on Dec 31, 2025.

Founded in 2000 and based in Tubingen, Germany, the company operates in the biotechnology sector, focusing on cancer immunotherapies. A proprietary platform called XPRESIDENT is utilized to identify and validate cancer-specific antigens. Adoptive cell therapies and bispecific T-cell receptors are subsequently developed for cancer treatment. The IMA101 product is generated through the ACTolog approach, employing T-cells from peripheral blood with targeted selectivity.

Immatics offers Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT.

Yes, Immatics is publicly traded on NASDAQ under the ticker symbol IMTX.

Immatics has 16 investors. Key investors include 3i Group, European Union, KfW, Bristol-Myers Squibb, and DH Capital.

Immatics operates through Immatics N.V..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available